Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard G. Ghalie, Sui Shen, Ruby F. Meredith

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a novel tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) as the targeting moiety in patients with B-cell non-Hodgkin lymphoma (NHL), and to characterize its pharmacokinetics and immunogenicity. All patients received B9E9FP (160 mg/m2 or 320 mg/m2); either 48 or 72 hours later, a synthetic clearing agent (sCA) was administered (45 mg/m2) to remove circulating unbound B9E9FP. 9OYttrium (90Y; 15 mCi/m2)/111In (5 mCi)-DOTA-biotin was injected 24 hours later. There were 15 patients enrolled in the study. B9E9FP had a mean plasma half-life (T1/2) of 25 ± 6 hours with a reduction in plasma level of more than 95% within 6 hours of sCA administration. 90Y/111In-DOTA-biotin infusion resulted in rapid tumor localization and urinary excretion. The ratio of average tumor to whole-body radiation dose was 49:1. No significant hematologic toxicities were noted in 12 patients. There were 2 patients who had hematologic toxicity related to progressive disease. There were 2 complete remissions (90 and 325 days) and one partial response (297 days). B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of 90Y-DOTA-biotin in this format is warranted.

Original languageEnglish (US)
Pages (from-to)227-236
Number of pages10
JournalBlood
Volume104
Issue number1
DOIs
StatePublished - Jul 1 2004

Fingerprint

Radioimmunotherapy
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Dosimetry
Fusion reactions
Cells
Tumors
Toxicity
Proteins
Plasmas
Pharmacokinetics
Streptavidin
Safety
Neoplasms
Radioisotopes
Whole-Body Irradiation
Half-Life
Tissue
Radiation
DOTA-biotin

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J., ... Meredith, R. F. (2004). Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood, 104(1), 227-236. https://doi.org/10.1182/blood-2003-09-3284

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. / Forero, Andres; Weiden, Paul L.; Vose, Julie M.; Knox, Susan J.; LoBuglio, Albert F.; Hankins, Jordan; Goris, Michael L.; Picozzi, Vincent J.; Axworthy, Don B.; Breitz, Hazel B.; Sims, Robert B.; Ghalie, Richard G.; Shen, Sui; Meredith, Ruby F.

In: Blood, Vol. 104, No. 1, 01.07.2004, p. 227-236.

Research output: Contribution to journalArticle

Forero, A, Weiden, PL, Vose, JM, Knox, SJ, LoBuglio, AF, Hankins, J, Goris, ML, Picozzi, VJ, Axworthy, DB, Breitz, HB, Sims, RB, Ghalie, RG, Shen, S & Meredith, RF 2004, 'Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma', Blood, vol. 104, no. 1, pp. 227-236. https://doi.org/10.1182/blood-2003-09-3284
Forero, Andres ; Weiden, Paul L. ; Vose, Julie M. ; Knox, Susan J. ; LoBuglio, Albert F. ; Hankins, Jordan ; Goris, Michael L. ; Picozzi, Vincent J. ; Axworthy, Don B. ; Breitz, Hazel B. ; Sims, Robert B. ; Ghalie, Richard G. ; Shen, Sui ; Meredith, Ruby F. / Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. In: Blood. 2004 ; Vol. 104, No. 1. pp. 227-236.
@article{00226bec6d8746819a0576c7193b4e3d,
title = "Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma",
abstract = "Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a novel tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) as the targeting moiety in patients with B-cell non-Hodgkin lymphoma (NHL), and to characterize its pharmacokinetics and immunogenicity. All patients received B9E9FP (160 mg/m2 or 320 mg/m2); either 48 or 72 hours later, a synthetic clearing agent (sCA) was administered (45 mg/m2) to remove circulating unbound B9E9FP. 9OYttrium (90Y; 15 mCi/m2)/111In (5 mCi)-DOTA-biotin was injected 24 hours later. There were 15 patients enrolled in the study. B9E9FP had a mean plasma half-life (T1/2) of 25 ± 6 hours with a reduction in plasma level of more than 95{\%} within 6 hours of sCA administration. 90Y/111In-DOTA-biotin infusion resulted in rapid tumor localization and urinary excretion. The ratio of average tumor to whole-body radiation dose was 49:1. No significant hematologic toxicities were noted in 12 patients. There were 2 patients who had hematologic toxicity related to progressive disease. There were 2 complete remissions (90 and 325 days) and one partial response (297 days). B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of 90Y-DOTA-biotin in this format is warranted.",
author = "Andres Forero and Weiden, {Paul L.} and Vose, {Julie M.} and Knox, {Susan J.} and LoBuglio, {Albert F.} and Jordan Hankins and Goris, {Michael L.} and Picozzi, {Vincent J.} and Axworthy, {Don B.} and Breitz, {Hazel B.} and Sims, {Robert B.} and Ghalie, {Richard G.} and Sui Shen and Meredith, {Ruby F.}",
year = "2004",
month = "7",
day = "1",
doi = "10.1182/blood-2003-09-3284",
language = "English (US)",
volume = "104",
pages = "227--236",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

AU - Forero, Andres

AU - Weiden, Paul L.

AU - Vose, Julie M.

AU - Knox, Susan J.

AU - LoBuglio, Albert F.

AU - Hankins, Jordan

AU - Goris, Michael L.

AU - Picozzi, Vincent J.

AU - Axworthy, Don B.

AU - Breitz, Hazel B.

AU - Sims, Robert B.

AU - Ghalie, Richard G.

AU - Shen, Sui

AU - Meredith, Ruby F.

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a novel tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) as the targeting moiety in patients with B-cell non-Hodgkin lymphoma (NHL), and to characterize its pharmacokinetics and immunogenicity. All patients received B9E9FP (160 mg/m2 or 320 mg/m2); either 48 or 72 hours later, a synthetic clearing agent (sCA) was administered (45 mg/m2) to remove circulating unbound B9E9FP. 9OYttrium (90Y; 15 mCi/m2)/111In (5 mCi)-DOTA-biotin was injected 24 hours later. There were 15 patients enrolled in the study. B9E9FP had a mean plasma half-life (T1/2) of 25 ± 6 hours with a reduction in plasma level of more than 95% within 6 hours of sCA administration. 90Y/111In-DOTA-biotin infusion resulted in rapid tumor localization and urinary excretion. The ratio of average tumor to whole-body radiation dose was 49:1. No significant hematologic toxicities were noted in 12 patients. There were 2 patients who had hematologic toxicity related to progressive disease. There were 2 complete remissions (90 and 325 days) and one partial response (297 days). B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of 90Y-DOTA-biotin in this format is warranted.

AB - Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a novel tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) as the targeting moiety in patients with B-cell non-Hodgkin lymphoma (NHL), and to characterize its pharmacokinetics and immunogenicity. All patients received B9E9FP (160 mg/m2 or 320 mg/m2); either 48 or 72 hours later, a synthetic clearing agent (sCA) was administered (45 mg/m2) to remove circulating unbound B9E9FP. 9OYttrium (90Y; 15 mCi/m2)/111In (5 mCi)-DOTA-biotin was injected 24 hours later. There were 15 patients enrolled in the study. B9E9FP had a mean plasma half-life (T1/2) of 25 ± 6 hours with a reduction in plasma level of more than 95% within 6 hours of sCA administration. 90Y/111In-DOTA-biotin infusion resulted in rapid tumor localization and urinary excretion. The ratio of average tumor to whole-body radiation dose was 49:1. No significant hematologic toxicities were noted in 12 patients. There were 2 patients who had hematologic toxicity related to progressive disease. There were 2 complete remissions (90 and 325 days) and one partial response (297 days). B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of 90Y-DOTA-biotin in this format is warranted.

UR - http://www.scopus.com/inward/record.url?scp=3042796950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042796950&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-09-3284

DO - 10.1182/blood-2003-09-3284

M3 - Article

C2 - 14996706

AN - SCOPUS:3042796950

VL - 104

SP - 227

EP - 236

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -